tbuckley/cabot-search huggingface dataset:
原発性硬化性胆管炎のゲノムワイド関連研究を行い,新たなリスク座位を同定し,炎症性腸疾患との遺伝的類似性を数値化した
Authors: JI Sun‐Gou, Kumasaka Natsuhiko, Liu Jimmy Z, Shah Tejas, Gutierrez‐Achury Javier, Ouwehand Willem H, Danesh John, Gaffney Daniel J, Anderson Carl A, Juran Brian D, Schlicht Erik M, Gulamhusein Aliya F, Eaton John E, Lazaridis Konstantinos N, Mucha Soeren, Ellinghaus David, Schreiber Stefan, Franke Andre, Folseraas Trine, Melum Espen, Boberg Kirsten M, Karlsen Tom H, Jostins Luke, Atkinson Elizabeth J, DE Andrade Mariza, Bergquist Annika, Vermeire Severine, Eksteen Bertus, Durie Peter R, Farkkila Martti, Mueller Tobias, Schramm Christoph, Sterneck Martina, Weismueller Tobias J, Manns Michael P, Gotthardt Daniel N, Braun Felix, Teufel Andreas, Laudes Mattias, Lieb Wolfgang, Jacobs Gunnar, Beuers Ulrich, Weersma Rinse K, Wijmenga Cisca, Marschall Hanns‐Ulrich, Milkiewicz Piotr, Pares Albert, Kontula Kimmo, Chazouilleres Olivier, Invernizzi Pietro, Goode Elizabeth, Spiess Kelly, Srivastava Brijesh, Mells George, Sandford Richard N, Rushbrook Simon M, Moore Carmel, Roberts David J, Sambrook Jennifer, Floreani Annarosa, Coltescu Catalina, Bowlus Christopher L, Luketic Velimir A, Odin Joseph A, Chopra Kapil B, Kowdley Kris, Chalasani Naga, Alexander Graeme, Chapman Roger W, Hirschfield Gideon M
Journal: Nature Genetics (2017)
SAT0677 The impact of disease activity during pregnancy in women with sle on the occurrence of preeclampsia and premature birth
Authors: ACG Skorpen, S Lydersen, I-M Gilboe, KÅ Salvesen, M Wallenius
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Pregnancy in women with systemic lupus erythematosus (SLE) is associated with an increased risk of complications such as preeclampsia and premature birth. Active disease is considered one of the risk factors. <h3>Objectives</h3> The aim of this study was to explore the impact of disease activity in pregnant women with SLE on preeclampsia and premature birth, and compare the occurrence with pregnancies from the general obstetric population. <h3>Methods</h3> We linked data from RevNatus with data from the Medical Birth Registry of Norway (MBRN). RevNatus is a Norwegian nationwide prospective observational register including women with an inflammatory rheumatic disease when planning pregnancy or after conception. The register was established in 2006 and is administered by the National advisory unit on pregnancy and rheumatic diseases. Women 18 years or older are recruited and followed-up in each trimester of pregnancy and at 6 weeks, 6 months and 12 months after birth. MBRN is a national birth registry. The population constituted all singleton live births recorded in MBRN in the period 2006 – 2014. The births in women diagnosed with SLE in MBRN and included in RevNatus formed the patient group (n=180). The references were all other births (n=498849). We performed logistic regression, and calculated OR for preeclampsia and premature birth in the patient population compared to the references from the general obstetric population. The target population was then split in two groups according to disease activity assessed in the 2nd trimester, and compared to references. <h3>Results</h3> Women with SLE had a significantly higher risk of preeclampsia and premature birth than references after adjustment for maternal age, parity and smoking (Table 1). Concerning preeclampsia, there was no significant difference in women with no disease activity compared to references, whereas active disease resulted in a significantly higher odds. We observed a two-fold and eight-fold increase in risk of premature birth in women with quiescent and active disease, respectively (Table 2). <h3>Conclusions</h3> Women with SLE have a higher risk of preeclampsia and premature birth than references from the general obstetric population. Women with active disease in pregnancy are most prone to these complications. <h3>Disclosure of Interest</h3> None declared
The Histologic Analysis of Mammary Tumors of Mice. III. Organoid Tumors&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Foulds, L.
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article The Histologic Analysis of Mammary Tumors of Mice. III. Organoid Tumors Get access L. Foulds L. Foulds Chester Beatty Research Institute, Institute of Cancer Research, Royal Cancer Hospital, London, England Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 17, Issue 6, December 1956, Pages 755–781, https://doi.org/10.1093/jnci/17.6.755 Published: 01 December 1956 Article history Received: 20 August 1956 Published: 01 December 1956
生体吸収性の弾性移植片を用いたin situ心臓弁組織工学ヒツジにおける12カ月フォローアップへの材料設計から【Powered by NICT】
Authors: Kluin Jolanda, Talacua Hanna, Smits Anthal I.P.M., Y Emmert Maximilian, C P Brugmans Marieke, S Fioretta Emanuela, E Dijkman Petra, H M Sontjens Serge, Duijvelshoff Renee, Dekker Sylvia, Janssen-van den Broek Marloes W.J.T., Lintas Valentina, Vink Aryan, P Hoerstrup Simon, M Janssen Henk, Y W Dankers Patricia, P T Baaijens Frank, V C Bouten Carlijn
Journal: Biomaterials (2017)
Address of Welcome<xref ref-type="fn" rid="fn1"><sup>1</sup></xref>
Authors: John R. Heller
Journal: JNCI Journal of the National Cancer Institute (1949)

Journal Article Address of Welcome Get access John R. Heller John R. Heller Director National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 2, October 1949, Pages 299–301, https://doi.org/10.1093/jnci/10.2.299 Published: 01 October 1949
Genetic Associations with Gestational Duration and Spontaneous Preterm Birth
Authors: Ge Zhang, Bjarke Feenstra, Jonas Bacelis, Xueping Liu, Lisa M. Muglia, Julius Juodakis, Daniel E. Miller, Nadia Litterman, Pan-Pan Jiang, Laura Russell, David A. Hinds, Youna Hu, Matthew T. Weirauch, Xiaoting Chen, Arun R. Chavan, Günter P. Wagner, Mihaela Pavličev, Mauris C. Nnamani, Jamie Maziarz, Minna K. Karjalainen, Mika Rämet, Verena Sengpiel, Frank Geller, Heather A. Boyd, Aarno Palotie, Allison Momany, Bruce Bedell, Kelli K. Ryckman, Johanna M. Huusko, Carmy R. Forney, Leah C. Kottyan, Mikko Hallman, Kari Teramo, Ellen A. Nohr, George Davey Smith, Mads Melbye, Bo Jacobsson, Louis J. Muglia
Journal: New England Journal of Medicine (2017)

Despite evidence that genetic factors contribute to the duration of gestation and the risk of preterm birth, robust associations with genetic variants have not been identified. We used large data sets that included the gestational duration to determine possible genetic associations.
Determining the Incidence of <i>Pneumocystis</i> Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis
Authors: Kyle T. Amber, Aniek Lamberts, Farzan Solimani, Arianna F. Agnoletti, Dario Didona, Ilona Euverman, Emanuele Cozzani, Lee Haur Yueh, Giovanni Di Zenzo, Yael Anne Leshem, Daniel Mimouni, Michael Hertl, Barbara Horvath
Journal: JAMA Dermatology (2017)

<h3>Importance</h3> <i>Pneumocystis</i>pneumonia (PCP) is a potentially lethal opportunistic infection that primary prophylaxis can help prevent. The risk of prophylactic therapy must be weighed against the incidence of PCP in the patient population. Prophylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, and pentamide. The indication for prophylaxis in immunocompromised patients without HIV is less well defined. Previously, an incidence of at least 3.5% has been proposed as a cutoff to justify prophylaxis. <h3>Objective</h3> To assess the incidence of PCP in patients with autoimmune blistering diseases receiving no routine prophylaxis. <h3>Design, Setting, and Participants</h3> This was a retrospective analysis of patient medical records to determine the incidence of PCP infections. The multicenter study was performed at tertiary care centers that provide care for patients with autoimmune blistering disease in Germany, Italy, Singapore, Israel, and the Netherlands. Patients had a confirmed diagnosis of pemphigus vulgaris/foliaceus, bullous pemphigoid, epidermolysis bullosa acquisita, mucous membrane pemphigoid/cicatricial pemphigoid, or anti-p200 pemphigoid. <h3>Main Outcomes and Measures</h3> To determine the incidence of PCP defined as patients with the<i>International Classification of Diseases, Ninth Revision (ICD-9)</i>, code 136.3, for PCP, or free text documentation of PCP occurring based on characteristic radiographic findings with elevated lactate dehydrogenase, or hospitalization for pneumonia with bronchioalveolar lavage demonstrating<i>Pneumocystis jiroveci</i>on confirmatory stains. <h3>Results</h3> A total of 801 patients with autoimmune blistering diseases were included in this study; their mean (SD) age was 66.5 (17.6) years, and a total of 465 (58%) were female. Only 1 patient developed PCP, resulting in an incidence rate of 0.1%. This incidence significantly fell below the recommended threshold of 3.5% (0.1% vs 3.5%, χ<sup>2</sup><sub>1</sub> = 27.0;<i>P</i> &lt; .001). This incidence was significantly lower than the previously reported incidence of PCP in all immunosuppressed dermatologic patients (0.1% vs 1.3%; χ<sup>2</sup><sub>1</sub> = 8.2;<i>P</i> = .004). <h3>Conclusions and Relevance</h3> Routine<i>Pneumocystis</i>prophylaxis for patients with autoimmune blistering diseases does not seem to be warranted. Patients with autoimmune blistering disease seem to have a lower risk of PCP than the general population of immunosuppressed dermatology patients. Risks of routine prophylaxis include hyperkalemia, hypoglycemia, photosensitivity, thrombocytopenia, and more rare adverse reactions.
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge
Authors: Boris Julg, Lawrence J. Tartaglia, Brandon F. Keele, Kshitij Wagh, Amarendra Pegu, Devin Sok, Peter Abbink, Stephen D. Schmidt, Keyun Wang, Xuejun Chen, M. Gordon Joyce, Ivelin S. Georgiev, Misook Choe, Peter D. Kwong, Nicole A. Doria-Rose, Khoa Le, Mark K. Louder, Robert T. Bailer, Penny L. Moore, Bette Korber, Michael S. Seaman, Salim S. Abdool Karim, Lynn Morris, Richard A. Koup, John R. Mascola, Dennis R. Burton, Dan H. Barouch
Journal: Science Translational Medicine (2017)

Neutralizing antibodies to the HIV-1 envelope V2 apex protect macaques against SHIV challenge at very low serum concentrations.
Epigenetic priming prior to pembrolizumab in microsatellite-stable (MSS) advanced colorectal cancer.
Authors: Adrian Gerard Murphy, Sharon White, Rosalind Walker, Eric R. Lutz, Nita Ahuja, Lei Zheng, Elizabeth M. Jaffee, Nilofer Saba Azad
Journal: Journal of Clinical Oncology (2016)

TPS3626 Background: Pembrolizumab has been shown to result in compelling responses and progression free survival in advanced MMR-d CRC. However, the vast majority (~95%) of patients with advanced CRC have MMR proficient (MMR-p) tumors which do not respond to PD1 blockade. Hypermethylation of DNA promoter regions by DNA methyltransferases (DNMT) and histone deacetylation by histone deacetylases (HDAC) result in the silencing of tumor suppressor genes. Preclinical studies have shown that combined HDAC/DNMT inhibition can induce susceptibility to immune checkpoint therapy and inhibit tumor growth by inducing re-expression of tumor suppressors silence by DNA methylation. Methods: This is a single institution, open-label, randomized pilot study (NCT02512172) enrolling patients with advanced MMR-p CRC who have progressed on ≥ 1 line of chemotherapy (n = 30). Patients are randomized to one of 3 arms: A: oral 5-azacitidine (5AZA, CC486), B: romidepsin or C: combined 5AZA and romidepsin. Patients will have a pre-treatment biopsy followed by 14 days of epigenetic therapy followed by a second biopsy. All groups then begin pembrolizumab 200 mg combined with epigenetic therapy until disease progression. Eligibility: Histologically confirmed MMR-p CRC and have received ≥ 1 line of chemotherapy but ≤ 3 lines, ECOG 0-1, measurable/biopsiable disease. Those with primary refractory disease are ineligible for this study There will be a safety run-in for all arms (n = 3 patients), if 0-1 patients have a DLT (dose limiting toxicity), accrual will continue, if ≥ 2 experience DLT, we will halt accrual to that arm. Toxicity is assessed using standard NCI CTCAE v4.0. Statistics: Primary endpoints include evaluation of changes in CD45R0+ve tumor infiltrating lymphocytes (memory T cells) in tumor biopsies and to determine safety/feasibility of these combined therapies. Secondary endpoints include estimating progression-free and overall survival. This study was activated in January 2016 and is expected to complete accrual within 12 months. Clinical trial information: NCT02512172.
Accuracy of Complete Blood Cell Counts to Identify Febrile Infants 60 Days or Younger With Invasive Bacterial Infections
Authors: Andrea T. Cruz, Prashant Mahajan, Bema K. Bonsu, Jonathan E. Bennett, Deborah A. Levine, Elizabeth R. Alpern, Lise E. Nigrovic, Shireen M. Atabaki, Daniel M. Cohen, John M. VanBuren, Octavio Ramilo, Nathan Kuppermann
Journal: JAMA Pediatrics (2017)

Clinicians often risk stratify young febrile infants for invasive bacterial infections (IBIs), defined as bacteremia and/or bacterial meningitis, using complete blood cell count parameters.To estimate the accuracy of individual complete blood cell count parameters to identify febrile infants with IBIs.Planned secondary analysis of a prospective observational cohort study comprising 26 emergency departments in the Pediatric Emergency Care Applied Research Network from 2008 to 2013. We included febrile (≥38°C), previously healthy, full-term infants younger than 60 days for whom blood cultures were obtained. All infants had either cerebrospinal fluid cultures or 7-day follow-up.We tested the accuracy of the white blood cell count, absolute neutrophil count, and platelet count at commonly used thresholds for IBIs. We determined optimal thresholds using receiver operating characteristic curves.Of 4313 enrolled infants, 1340 (31%; 95% CI, 30% to 32%) were aged 0 to 28 days, 2412 were boys (56%), and 2471 were white (57%). Ninety-seven (2.2%; 95% CI, 1.8% to 2.7%) had IBIs. Sensitivities were low for common complete blood cell count parameter thresholds: white blood cell count less than 5000/µL, 10% (95% CI, 4% to 16%) (to convert to 109 per liter, multiply by 0.001); white blood cell count ≥15 000/µL, 27% (95% CI, 18% to 36%); absolute neutrophil count ≥10 000/µL, 18% (95% CI, 10% to 25%) (to convert to × 109 per liter, multiply by 0.001); and platelets <100 × 103/µL, 7% (95% CI, 2% to 12%) (to convert to × 109 per liter, multiply by 1). Optimal thresholds for white blood cell count (11 600/µL), absolute neutrophil count (4100/µL), and platelet count (362 × 103/µL) were identified in models that had areas under the receiver operating characteristic curves of 0.57 (95% CI, 0.50-0.63), 0.70 (95% CI, 0.64-0.76), and 0.61 (95% CI, 0.55-0.67), respectively.No complete blood cell count parameter at commonly used or optimal thresholds identified febrile infants 60 days or younger with IBIs with high accuracy. Better diagnostic tools are needed to risk stratify young febrile infants for IBIs.
空間的および時間的に精密な制御された放出によるin vivoでの標的療法のためのFRET誘導,NIR応答性バブル生成リポソーム系【Powered by NICT】
Authors: Chuang Er-Yuan, Lin Chia-Chen, Chen Ko-Jie, Wan De-Hui, Lin Kun-Ju, Ho Yi-Cheng, Lin Po-Yen, Sung Hsing-Wen
Journal: Biomaterials (2016)
Inhaled budesonide for acute mountain sickness
Authors: Robert Naeije, Erik R. Swenson
Journal: European Respiratory Journal (2017)

In the present issue of the European Respiratory Journal , Berger et al. [1] report the lack of efficacy of inhaled budesonide for the prevention of acute mountain sickness (AMS). This small well-designed study was undertaken to verify or refute the provocative finding of robust protection with budesonide against AMS reported by Chinese colleagues in 2014 [2] and 2015 [3]. In the presently reported study, 50 healthy volunteers were randomly assigned to inhale twice daily budesonide 200 μg, budesonide 800 μg or a placebo 1 day prior and during climbing in less than 48 h to an altitude of 4559 m. Such a rapid active ascent is known to be associated with a more than 50% incidence of AMS symptomatology [4]. Accordingly, AMS indeed occurred in 53% of the subjects in the placebo group, and in 56% and 76% of the subjects assigned to the 200 μg and 800 μg budesonide groups, respectively. Between group differences were not significant. Clearly, inhaled budesonide did not prevent acute mountain sickness. Inhaled corticosteroids are ineffective for the treatment of acute mountain sickness <http://ow.ly/gz0i30eawqn>
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study
Authors: Tsutomu Takeuchi, Carter Thorne, George Karpouzas, Shihong Sheng, Weichun Xu, Ravi Rao, Kaiyin Fei, Benjamin Hsu, Paul P Tak
Journal: Annals of the Rheumatic Diseases (2017)

Objectives Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine. The phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group SIRROUND-D study (ClinicalTrials.gov identifier NCT01604343 ) evaluated the efficacy and safety of sirukumab in patients with active RA refractory to disease-modifying antirheumatic drugs. Methods Patients were randomised 1:1:1 to treatment with sirukumab 100 mg every 2 weeks, 50 mg every 4 weeks or placebo every 2 weeks subcutaneously. Results through week 52 are reported. Results Of 1670 randomised patients, significantly more patients achieved American College of Rheumatology 20% (ACR20) response at week 16 (coprimary endpoint) with sirukumab 100 mg every 2 weeks (53.5%) or 50 mg every 4 weeks (54.8%) versus placebo (26.4%; both p&lt;0.001). Mean (SD) change from baseline in modified Sharp/van der Heijde score at week 52 (coprimary endpoint) was significantly lower with sirukumab (100 mg every 2 weeks: 0.46 (3.26); 50 mg every 4 weeks: 0.50 (2.96)) versus placebo (3.69 (9.25); both p&lt;0.001). All major secondary endpoints (week 24 Health Assessment Questionnaire–Disability Index change from baseline, ACR50 response, 28-joint Disease Activity Score based on C reactive protein and major clinical response (ACR70 for six continuous months by week 52)) were met. The most common adverse events with sirukumab were elevated liver enzymes, upper respiratory tract infection, injection site erythema and nasopharyngitis. Conclusions Sirukumab 100 mg every 2 weeks and 50 mg every 4 weeks led to significant reductions in RA symptoms, inhibition of structural damage progression and physical function and quality of life improvements, with an expected safety profile. Trial registration number NCT01604343; Results.
How effective is bronchial thermoplasty for severe asthma in clinical practice?
Authors: Neil C. Thomson, Pascal Chanez
Journal: European Respiratory Journal (2017)

Bronchial thermoplasty is an intervention developed for the treatment of asthma through the delivery of radio frequency energy to the airways [1, 2]. Evidence for the efficacy and safety of bronchial thermoplasty in severe asthma is based on the results of three randomised controlled trials [3–5]. Two trials compared bronchial thermoplasty with usual care, the Asthma Intervention Research (AIR) trial [3] and the Research in Severe Asthma (RISA) trial [4], whereas the third trial (AIR2) compared bronchial thermoplasty with a sham procedure [5]. The AIR2 trial reported improved asthma quality of life questionnaire (AQLQ) scores, reduced severe exacerbations and decreased emergency department visits in the post-bronchial thermoplasty treatment period [5]. Bronchial thermoplasty was associated with a short-term increase in asthma-related symptoms and hospital admissions for asthma during the treatment phase [3–5]. Follow-up observational studies to date support the long-term safety of the procedure, based on unchanged rates of respiratory adverse events, lung function, serial computed tomography scans and rates of hospital admissions or emergency department visits in years 2–5 following the AIR [6], RISA [7] and AIR2 trials [8]. A Cochrane systematic review of the trials concluded that there was a modest clinical benefit in asthma quality of life and a reduction in exacerbation rates 12 months after bronchial thermoplasty [9]. In 2010, the Food and Drug Administration (FDA) gave premarket approval for the Alair bronchial thermoplasty system (Boston Scientific, Marlborough, MA, USA) as a treatment for severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and a long-acting β-agonist [10]. Bronchial thermoplasty is also approved for the treatment of asthma in the European Union and in many countries worldwide. Bronchial thermoplasty can be effective in patients who often have features of more severe asthma than in AIR2 <http://ow.ly/Qv5730cTIuB>
The Character Heads by Franz Messerschmidt: An Example of Art Therapy
Authors: Antonio Perciaccante, Alessia Coralli
Journal: American Journal of Psychiatry (2017)

A relationship between psychiatric illnesses and creativity is supported by the case of the German sculptor Franz Xaver Messerschmidt (1736-1783) and his most famous artistic work, the collection known as the Character Heads.It comprises 69 (49 actually known) marble, alabaster, and bronze busts, mostly self-portraits, characterized by facial distortions and
Routine Clinical Testing for Actionable Mutations in CLL Using Endcll Assay V1: The Initial MD Anderson Experience
Authors: Keyur P. Patel, Rajesh Singh, Mark Routbort, C. Cameron Yin, Rashmi Kanagal Shamanna, Nitin Jain, Xinyan Lu, Sherry Pierce, Michael Keating, Hagop M. Kantarjian, L. Jeffrey Medeiros, Raja Luthra, William G. Wierda
Journal: Blood (2016)
聴覚ニューロンの誘導成長:ギャップレスニューラル‐電極界面への生物活性粒子【Powered by NICT】
Authors: Li Hao, Edin Fredrik, Hayashi Hisamitsu, Gudjonsson Olafur, Danckwardt-Lilliestrom Niklas, Engqvist Hakan, Rask-Andersen Helge, Xia Wei
Journal: Biomaterials (2017)
Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery
Authors: Albert Lo, Chin-Tarng Lin, Han-Chung Wu
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

5610 

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify a novel peptide which binds specifically to HCC cells. In vitro , the targeting phage was shown to bind to HCC cell lines by ELISA and flow cytometry analysis. In vivo , targeting phage homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. This homing ability could be competitively inhibited by synthetic peptide. Immunohistochemical staining confirmed that targeting phage localized to tumor tissues and that it could not be detected in peptide-competed tumor tissues. In addition, targeting phage recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31). With the conjugation of targeting peptide and liposomal doxorubicin, the targeted drug delivery system enhanced the therapeutic efficacy against HCC xenografts through enhanced tumor apoptosis and decreased tumor angiogenesis. Our results indicate that targeting peptide has the potential to improve the systemic treatment of patients with advanced HCC.
Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification
Authors: Alessandro Lagana, Deepak Perumal, Violetta V Leshchenko, Pei-Yu Kuo, Brian Kidd, Jonathan J Keats, Mary Derome, Jennifer Yesil, Daniel Auclair, Deepu Madduri, Ajai Chari, Hearn Jay Cho, Bart Barlogie, Sundar Jagannath, Joel Dudley, Samir Parekh
Journal: Blood (2016)